Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China.
To investigate the multi-infection patterns and type competition for human papillomavirus (HPV) in Chinese clinic attending women and evaluate the association between the infection status and cancer risk. Three hundred and thirty-two HPV-DNA-positive samples were genotyped for 21 HPVs and tested for 13 types of HPV neutralizing antibody using pseudoviron-based assay. Odds ratios (ORs) were calculated to evaluate the coinfection patterns for both DNA and neutralizing antibody (NAb), and the associations of HSIL+ with HPV DNA and NAb. Of the 332 HPV-DNA-positive subjects, 279 (84.0%) were detected as NAb positive. Multi-positive results were identified in 23.2% (77/332) HPV DNA tests and 60.2% (168/279) HPV NAb assays. The NAb titers for the multiple-positive samples (geometric mean 214) were significantly higher than the single-positive samples (geometric mean 114) (P < 0.01). HPV16-HPV52 was identified as a type-competition pair for both HPV DNA (OR = 0.09; 95%CI = 0.02-0.42) and NAb (OR = 0.27; 95%CI = 0.11-0.69) data. Compared to other types, HPV16 DNA was associated significantly with high risk of HSIL+ (OR = 2.57; 95%CI = 1.23-5.38). HPV16-HPV52 was identified as a potential type-competition pair, which might result in the type modulation with the implementation of the approved bi- or quadri-valent vaccines. J. Med. Virol. 88:1989-1998, 2016. © 2016 Wiley Periodicals, Inc.
['Nie|Jianhui|J|', 'Liu|Jianhua|J|', 'Xie|Hui|H|', 'Sun|Zhengrong|Z|', 'Zhao|Juan|J|', 'Chen|Qingqing|Q|', 'Liu|Yangyang|Y|', 'Huang|Weijin|W|', 'Ruan|Qiang|Q|', 'Wang|Youchun|Y|']
D000328:Adult D000554:Ambulatory Care Facilities D057134:Antibodies, Neutralizing D000914:Antibodies, Viral D002681:China D060085:Coinfection D005260:Female D005838:Genotype D061809:Human Papillomavirus DNA Tests D052162:Human papillomavirus 16 D006801:Humans D016017:Odds Ratio D027383:Papillomaviridae D030361:Papillomavirus Infections D053918:Papillomavirus Vaccines D002583:Uterine Cervical Neoplasms
human papillomavirus neutralization vaccine